Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Covalon Technologies Ltd CVALF


Primary Symbol: V.COV

Covalon Technologies Ltd. is a Canada-based patient-driven medical device company that provides healthcare solutions for advanced wound care, infection control, and medical device coatings. The Company's solutions are designed for patients and made for care providers. The Company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold... see more

TSXV:COV - Post Discussion

Covalon Technologies Ltd > Interim CFO and operational status
View:
Post by Gulliver1909 on Jan 14, 2022 4:51pm

Interim CFO and operational status

Timely reaction. I think they found a very good interim CFO within a short period of time (3 weeks).

Buys them time to find a very good new CFO.

I am really curious abouth the first quarter and current operational status.

Fourth quarter of 2021 was impressive with a 1 million $ net profit. IF they can repeat that in the current year would lead to  4 million $ net profit per your or a price sales ratio of less than 10 (in regard of the cash position).

Quite a steal.

However I do not know if COVID did again put pressure on the operating results again - media talking aobut overcrowed hospitals again in the US due to the Omicron variant.
Comment by Gulliver1909 on Jan 15, 2022 2:27am
"if they can repeat that in the current year would lead to 4 million $ net profit per year or a price sales ratio of less than 10 (in regard of the cash position)." => of course I am talking about price-earnings-ratio. not price sales. price sales is more like a 1.x ratio..... dirty cheap for a profitable, growing medtech company. By the way Linkedin indicates that Covalon ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities